Identification of potential therapeutic targets in urothelial bladder carcinoma of Chinese population by targeted next-generation sequencing

References

• Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66. doi:10.3322/canjclin.57.1.43.
   PubMed Web of Science ®Google Scholar
• McGuire S. World Cancer Report 2014. World Health Organization, International Agency for Research on Cancer, WHO Press: Geneva (Switzerland), Advances in nutrition 2016; 7:418-9; 2015
   Google Scholar
• Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–2917. doi:10.1002/ijc.25516.
   PubMed Web of Science ®Google Scholar
• Wu C, Zheng X, Li X, Fesler A, Hu W, Chen L, Xu B, Wang Q, Tong A, Burke S, et al. Reduction of gastric cancer proliferation and invasion by miR-15a mediated suppression of Bmi-1 translation. Oncotarget. 2016;7(12):14522–14536. doi:10.18632/oncotarget.7392.
   PubMedGoogle Scholar
• Garcia-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, Tardón A, Serra C, Carrato A, García-Closas R, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet. 2005;366(9486):649–659. doi:10.1016/S0140-6736(05)67137-1.
   PubMed Web of Science ®Google Scholar
• LaRue H, Allard P, Simoneau M, Normand C, Pfister C, Moore L, Meyer F, Têtu B, Fradet Y. P53 point mutations in initial superficial bladder cancer occur only in tumors from current or recent cigarette smokers. Carcinogenesis. 2000;21:101–106. doi:10.1093/carcin/21.1.101.
   PubMed Web of Science ®Google Scholar
• Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. Jama. 2011;306:737–745. doi:10.1001/jama.2011.1142.
   PubMed Web of Science ®Google Scholar
• Boffetta P. Tobacco smoking and risk of bladder cancer. Scand J Urol Nephrol Suppl. 2008:45–54. doi:10.1080/03008880802283664
   PubMedGoogle Scholar
• Ugnat AM, Luo W, Semenciw R, Mao Y. Occupational exposure to chemical and petrochemical industries and bladder cancer risk in four western Canadian provinces. Chronic Dis Can. 2004;25:7–15.
   PubMedGoogle Scholar
• Benbrahim-Tallaa L, Baan RA, Grosse Y, Lauby-Secretan B, El Ghissassi F, Bouvard V, Guha N, Loomis D, Straif K. Carcinogenicity of diesel-engine and gasoline-engine exhausts and some nitroarenes. Lancet Oncol. 2012;13(7):663–664. doi:10.1016/S1470-2045(12)70280-2.
   PubMed Web of Science ®Google Scholar
• Djousse L, Schatzkin A, Chibnik LB, D’Agostino RB, Kreger BE, Ellison RC. Alcohol consumption and the risk of bladder cancer in the Framingham Heart Study. J Natl Cancer Inst. 2004;96:1397–1400. doi:10.1093/jnci/djh263.
   PubMedGoogle Scholar
• Lin CJ, Gong HY, Tseng HC, Wang WL, Wu JL. miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. Biochem Biophys Res Commun. 2008;375:315–320. doi:10.1016/j.bbrc.2008.07.154.
   PubMed Web of Science ®Google Scholar
• Weibull CE, Eloranta S, Altman D, Johansson AL, Lambe M. Childbearing and the risk of bladder cancer: a nationwide population-based cohort study. Eur Urol. 2013;63:733–738. doi:10.1016/j.eururo.2013.01.005.
   PubMed Web of Science ®Google Scholar
• Karkoulis PK, Stravopodis DJ, Margaritis LH, Voutsinas GE. 17-Allylamino-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells. BMC Cancer. 2010;10:481. doi:10.1186/1471-2407-10-481.
   PubMed Web of Science ®Google Scholar
• Konstantakou EG, Voutsinas GE, Velentzas AD, Basogianni AS, Paronis E, Balafas E, Kostomitsopoulos N, Syrigos KN, Anastasiadou E, Stravopodis DJ. 3-BrPA eliminates human bladder cancer cells with highly oncogenic signatures via engagement of specific death programs and perturbation of multiple signaling and metabolic determinants. Mol Cancer. 2015;14:135. doi:10.1186/s12943-015-0399-9.
   PubMed Web of Science ®Google Scholar
• Castillo-Martin M, Domingo-Domenech J, Karni-Schmidt O, Matos T, Cordon-Cardo C. Molecular pathways of urothelial development and bladder tumorigenesis. Urol Oncol. 2010;28:401–408. doi:10.1016/j.urolonc.2009.04.019.
   PubMed Web of Science ®Google Scholar
• Racioppi M, Di Gianfrancesco L, Ragonese M, Palermo G, Sacco E, Bassi P. The challenges of Bacillus of Calmette-Guerin (BCG) therapy for high risk non muscle invasive bladder cancer treatment in older patients. J Geriatr Oncol. 2018;9(5):507–512. doi:10.1016/j.jgo.2018.03.020.
   PubMed Web of Science ®Google Scholar
• Dougherty DW, Gonsorcik VK, Harpster LE, Trussell JC, Drabick JJ. Superficial bladder cancer metastatic to the lungs: two case reports and review of the literature. Urology. 2009;73:210:e3–5.
   Web of Science ®Google Scholar
• Chamie K, Litwin MS, Bassett JC, Daskivich TJ, Lai J, Hanley JM, Konety BR, Saigal CS. Recurrence of high-risk bladder cancer: a population-based analysis. Cancer. 2013;119(17):3219–3227. doi:10.1002/cncr.28147.
   PubMed Web of Science ®Google Scholar
• van den Bosch S, Alfred Witjes J. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol. 2011;60:493–500. doi:10.1016/j.eururo.2011.05.045.
   PubMed Web of Science ®Google Scholar
• Milowsky MI, Rumble RB, Booth CM, Gilligan T, Eapen LJ, Hauke RJ, Boumansour P, Lee CT. Guideline on muscle-invasive and metastatic bladder cancer (European association of urology guideline): American society of clinical oncology clinical practice guideline endorsement. J Clin Oncol. 2016;34:1945–1952. doi:10.1200/JCO.2015.65.9797.
   PubMed Web of Science ®Google Scholar
• Hovelson DH, Udager AM, McDaniel AS, Grivas P, Palmbos P, Tamura S, Lazo de la Vega L, Palapattu G, Veeneman B, El-Sawy L. Targeted DNA and RNA sequencing of paired urothelial and squamous bladder cancers reveals discordant genomic and transcriptomic events and unique therapeutic implications. Eur Urol. 2018;74(6):741–753. doi:10.1016/j.eururo.2018.06.047.
   PubMed Web of Science ®Google Scholar
• Mendiratta P, Grivas P. Emerging biomarkers and targeted therapies in urothelial carcinoma. Ann Transl Med. 2018;6(12):250. doi:10.21037/atm.2018.05.49.
   PubMed Web of Science ®Google Scholar
• Kim PH, Cha EK, Sfakianos JP, Iyer G, Zabor EC, Scott SN, Ostrovnaya I, Ramirez R, Sun A, Shah R, et al. Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder. Eur Urol. 2015;67(2):198–201. doi:10.1016/j.eururo.2014.06.050.
   PubMed Web of Science ®Google Scholar
• Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2015;15(1):25–41. doi:10.1038/nrc3817.
   PubMed Web of Science ®Google Scholar
• Pietzak EJ, Bagrodia A, Cha EK, Drill EN, Iyer G, Isharwal S, Ostrovnaya I, Baez P, Li Q, Berger MF, et al. Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets. Eur Urol. 2017;72(6):952–959. doi:10.1016/j.eururo.2017.05.032.
   PubMed Web of Science ®Google Scholar
• Czerniak B, Cohen GL, Etkind P, Deitch D, Simmons H, Herz F, Koss LG. Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas. Hum Pathol. 1992;23(11):1199–1204. doi:10.1016/0046-8177(92)90285-B.
   PubMed Web of Science ®Google Scholar
• Billerey C, Chopin D, Aubriot-Lorton M-H, Ricol D, Gil Diez de Medina S, Van RB, Bralet M-P, Lefrere-Belda M-A, Lahaye J-B, Abbou CC. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol. 2001;158(6):1955–1959. doi:10.1016/S0002-9440(10)64665-2.
   PubMed Web of Science ®Google Scholar
• van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res. 2001;61:1265–1268.
   PubMed Web of Science ®Google Scholar
• Knowles MA, Williamson M. Mutation of H-ras is infrequent in bladder cancer: confirmation by single-strand conformation polymorphism analysis, designed restriction fragment length polymorphisms, and direct sequencing. Cancer Res. 1993;53:133–139.
   PubMed Web of Science ®Google Scholar
• Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen S-C, Nichols PW, Skinner DG, Jones PA, Cote RJ, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med. 1994;331(19):1259–1264. doi:10.1056/NEJM199411103311903.
   PubMed Web of Science ®Google Scholar
• Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF, Lerner SP. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol. 2004;22(6):1014–1024. doi:10.1200/JCO.2004.03.118.
   PubMed Web of Science ®Google Scholar
• Schroeder JC, Conway K, Li Y, Mistry K, Bell DA, Taylor JA. p53 mutations in bladder cancer: evidence for exogenous versus endogenous risk factors. Cancer Res. 2003;63:7530–7538.
   PubMed Web of Science ®Google Scholar
• Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38:e164. doi:10.1093/nar/gkq603.
   PubMed Web of Science ®Google Scholar
• Sibley K, Stern P, Knowles MA. Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours. Oncogene. 2001;20:4416–4418. doi:10.1038/sj.onc.1204543.
   PubMed Web of Science ®Google Scholar
• Karoui M, Hofmann-Radvanyi H, Zimmermann U, Couvelard A, Degott C, Faridoni-Laurens L, Ahomadegbe J-C, Gazzeri S, Brambilla E, Clerici T. No evidence of somatic FGFR3 mutation in various types of carcinoma. Oncogene. 2001;20(36):5059–5061. doi:10.1038/sj.onc.1204651.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507:315–322. doi:10.1038/nature12965.
   PubMed Web of Science ®Google Scholar
• Pandith AA, Shah ZA, Siddiqi MA. Oncogenic role of fibroblast growth factor receptor 3 in tumorigenesis of urinary bladder cancer. Urol Oncol. 2013;31:398–406. doi:10.1016/j.urolonc.2010.07.014.
   PubMed Web of Science ®Google Scholar
• Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP, Radvanyi F. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet. 1999;23:18–20. doi:10.1038/12615.
   PubMed Web of Science ®Google Scholar
• Lv S, Ji L, Chen B, Liu S, Lei C, Liu X, Qi X, Wang Y, Lai-Han Leung E, Wang H. Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4. Oncogene. 2018;37(10):1354–1368. doi:10.1038/s41388-017-0026-x.
   PubMed Web of Science ®Google Scholar
• He K, An Z, Wang Q, Li T, Li Z, Chen J, Li W, Wang T, Ji J, Feng G, et al. CACNA1C, schizophrenia and major depressive disorder in the Han Chinese population. Br J Psychiatry. 2014;204(1):36–39. doi:10.1192/bjp.bp.113.126979.
   PubMed Web of Science ®Google Scholar
• Hamshere ML, Walters JT, Smith R, Richards AL, Green E, Grozeva D, Jones I, Forty L, Jones L, Gordon-Smith K, et al. Genome-wide significant associations in schizophrenia to ITIH3/4, CACNA1C and SDCCAG8, and extensive replication of associations reported by the Schizophrenia PGC. Mol Psychiatry. 2013;18(6):708–712. doi:10.1038/mp.2012.67.
   PubMed Web of Science ®Google Scholar
• Zhang J, Vlasevska S, Wells VA, Nataraj S, Holmes AB, Duval R, Meyer SN, Mo T, Basso K, Brindle PK, et al. The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell Lymphoma. Cancer Discov. 2017;7(3):322–337. doi:10.1158/2159-8290.CD-16-1417.
   PubMed Web of Science ®Google Scholar
• Kretsovali A, Agalioti T, Spilianakis C, Tzortzakaki E, Merika M, Papamatheakis J. Involvement of CREB binding protein in expression of major histocompatibility complex class II genes via interaction with the class II transactivator. Mol Cell Biol. 1998;18(11):6777–6783. doi:10.1128/MCB.18.11.6777.
   PubMed Web of Science ®Google Scholar
• Martin GS. Cell signaling and cancer. Cancer Cell. 2003;4(3):167–174. doi:10.1016/S1535-6108(03)00216-2.
   PubMedGoogle Scholar
• Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006;441:424–430. doi:10.1038/nature04869.
   PubMed Web of Science ®Google Scholar
• Guo G, Sun X, Chen C, Wu S, Huang P, Li Z, Dean M, Huang Y, Jia W, Zhou Q, et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet. 2013;45(12):1459–1463. doi:10.1038/ng.2798.
   PubMed Web of Science ®Google Scholar
• Wu TO S, Xing N, Jiang L, Wan S, Wang C, Zhang X, Yang F, Huang Y. Zhiming Cai Whole-genome sequencing identifies ADGRG6 enhancer mutations and FRS2 duplications as angiogenesis-related drivers in bladder cancer. Nat Commun. 2019;10:720. doi:10.1038/s41467-019-08576-5.
   PubMed Web of Science ®Google Scholar
• Gui Y, Guo G, Huang Y, Hu X, Tang A, Gao S, Wu R, Chen C, Li X, Zhou L, et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet. 2011;43(9):875–878. doi:10.1038/ng.907.
   PubMed Web of Science ®Google Scholar
• Pan H, Xu X, Wu D, Qiu Q, Zhou S, He X, Zhou Y, Qu P, Hou J, He J, et al. Novel somatic mutations identified by whole-exome sequencing in muscle-invasive transitional cell carcinoma of the bladder. Oncol Lett. 2016;11(2):1486–1492. doi:10.3892/ol.2016.4094.
   PubMed Web of Science ®Google Scholar
• Zaak D, Ohlmann C, Stenzl A. Current and established diagnostic modalities for bladder cancer. Urologe A. 2018;57(6):657–664. doi:10.1007/s00120-018-0650-2.
   PubMedGoogle Scholar
• Lorente D, Olmos D, Mateo J, Dolling D, Bianchini D, Seed G, Flohr P, Crespo M, Figueiredo I, Miranda S, et al. Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts. Ann Oncol. 2018;29(7):1554–1560. doi:10.1093/annonc/mdy172.
   PubMed Web of Science ®Google Scholar
• Hashimoto M, Tanaka F, Yoneda K, Takuwa T, Kuroda A, Matsumoto S, Okumura Y, Kondo N, Tsujimura T, Nakano T, et al. The clinical value of circulating tumour cells (CTCs) in patients undergoing pulmonary metastasectomy for metastatic colorectal cancer. J Thorac Dis. 2018;10(3):1569–1577. doi:10.21037/jtd.2018.03.05.
   PubMed Web of Science ®Google Scholar
• Muscella A, Calabriso N, Vetrugno C, Fanizzi FP, De Pascali SA, Storelli C, Marsigliante S. The platinum (II) complex [Pt(O,O’-acac)(gamma-acac)(DMS)] alters the intracellular calcium homeostasis in MCF-7 breast cancer cells. Biochem Pharmacol. 2011;81:91–103. doi:10.1016/j.bcp.2010.09.012.
   PubMed Web of Science ®Google Scholar
• Sehgal P, Szalai P, Olesen C, Praetorius HA, Nissen P, Christensen SB, Engedal N, Møller JV. Inhibition of the sarco/endoplasmic reticulum (ER) Ca 2+ -ATPase by thapsigargin analogs induces cell death via ER Ca 2+ depletion and the unfolded protein response. J Biol Chem. 2017;292(48):19656–19673. doi:10.1074/jbc.M117.796920.
   PubMed Web of Science ®Google Scholar